New hope for liver cancer patients in Resource-Limited settings
NCT ID NCT07408804
Summary
This study aims to find out if combining a targeted procedure (TACE) with a cancer drug (lenvatinib) works better than the drug alone for treating advanced liver cancer that cannot be surgically removed. It will involve 40 patients and focuses on real-world settings where access to advanced procedures is limited. The goal is to provide clearer guidance for doctors on the best treatment options for their patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Hepatology, Bangladesh Medical University
RECRUITINGDhaka, 1000, Bangladesh
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.